# Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/management-of-immune-related-adverse-events-in-patients-treated-with-immune/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Julie R. Brahmer,Christina Lacchetti,Bryan J. Schneider,Michael B. Atkins,Kelly Brassil,Jeffrey M. Caterino,Ian Chau,Marc S. Ernstoff,Jennifer M. Gardner,Pamela Ginex,Sigrun Hallmeyer,Jennifer Holter Chakrabarty,Natasha B. Leighl,Jennifer S. Mammen,David F. McDermott,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Porter,Igor Puzanov,Cristina Reichner,Bianca Santomasso,Carole Seigel,Alexander I. Spira,María E. Suarez‐Almazor,Yinghong Wang,Jeffrey S. Weber,Jedd D. Wolchok,John A. Thompson |
| Citations | 3,734 |
| DOI | 10.1200/jco.2017.77.6385 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/6481621 |
| OpenAlex ID | https://openalex.org/W2786816161 |
| PMID | 29442540 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Julie R. Brahmer](https://scholariq.org/researchers/julie-r-brahmer/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Neuroblastoma Research and Treatments](https://scholariq.org/topics/neuroblastoma-research-and-treatments/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.